Market Closed -
Bombay S.E.
11:00:53 28/06/2024 BST
|
5-day change
|
1st Jan Change
|
336
INR
|
+0.83%
|
|
+3.67%
|
-10.58%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,760
|
2,932
|
2,838
|
6,508
|
9,394
|
8,409
|
Enterprise Value (EV)
1 |
3,542
|
3,661
|
3,705
|
8,174
|
11,942
|
12,384
|
P/E ratio
|
18.2
x
|
18
x
|
12.6
x
|
7.83
x
|
13.2
x
|
19.5
x
|
Yield
|
0.25%
|
-
|
-
|
0.37%
|
0.44%
|
0.33%
|
Capitalization / Revenue
|
0.84
x
|
0.79
x
|
0.69
x
|
0.99
x
|
1.38
x
|
1.25
x
|
EV / Revenue
|
1.08
x
|
0.99
x
|
0.9
x
|
1.24
x
|
1.76
x
|
1.84
x
|
EV / EBITDA
|
8.97
x
|
7.96
x
|
7.14
x
|
5.89
x
|
9.79
x
|
11.3
x
|
EV / FCF
|
-56.8
x
|
105
x
|
-33.6
x
|
-8.74
x
|
-11.3
x
|
-7.25
x
|
FCF Yield
|
-1.76%
|
0.95%
|
-2.98%
|
-11.4%
|
-8.82%
|
-13.8%
|
Price to Book
|
2.43
x
|
2.27
x
|
1.87
x
|
2.52
x
|
2.86
x
|
2.29
x
|
Nbr of stocks (in thousands)
|
27,598
|
27,598
|
27,598
|
27,598
|
27,598
|
27,598
|
Reference price
2 |
100.0
|
106.2
|
102.8
|
235.8
|
340.4
|
304.7
|
Announcement Date
|
21/08/18
|
07/09/19
|
06/10/20
|
08/09/21
|
07/09/22
|
07/09/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
3,271
|
3,702
|
4,107
|
6,570
|
6,799
|
6,733
|
EBITDA
1 |
394.9
|
459.7
|
518.8
|
1,387
|
1,220
|
1,094
|
EBIT
1 |
284.1
|
345.6
|
397.5
|
1,226
|
1,043
|
821.9
|
Operating Margin
|
8.69%
|
9.34%
|
9.68%
|
18.66%
|
15.34%
|
12.21%
|
Earnings before Tax (EBT)
1 |
226.8
|
241.7
|
324.5
|
1,188
|
896.8
|
582.2
|
Net income
1 |
151.9
|
163.1
|
225
|
831.1
|
713.9
|
430.2
|
Net margin
|
4.64%
|
4.41%
|
5.48%
|
12.65%
|
10.5%
|
6.39%
|
EPS
2 |
5.502
|
5.910
|
8.153
|
30.11
|
25.87
|
15.59
|
Free Cash Flow
1 |
-62.32
|
34.78
|
-110.3
|
-935.5
|
-1,053
|
-1,708
|
FCF margin
|
-1.91%
|
0.94%
|
-2.69%
|
-14.24%
|
-15.49%
|
-25.36%
|
FCF Conversion (EBITDA)
|
-
|
7.57%
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
21.32%
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.2500
|
-
|
-
|
0.8750
|
1.500
|
1.000
|
Announcement Date
|
21/08/18
|
07/09/19
|
06/10/20
|
08/09/21
|
07/09/22
|
07/09/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
782
|
729
|
868
|
1,666
|
2,548
|
3,975
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.981
x
|
1.585
x
|
1.673
x
|
1.201
x
|
2.089
x
|
3.633
x
|
Free Cash Flow
1 |
-62.3
|
34.8
|
-110
|
-936
|
-1,053
|
-1,708
|
ROE (net income / shareholders' equity)
|
14.3%
|
13.4%
|
16%
|
38.1%
|
24.3%
|
12.4%
|
ROA (Net income/ Total Assets)
|
7.29%
|
8.07%
|
8.39%
|
17.6%
|
10.5%
|
6.33%
|
Assets
1 |
2,084
|
2,020
|
2,683
|
4,711
|
6,825
|
6,795
|
Book Value Per Share
2 |
41.20
|
46.80
|
54.90
|
93.60
|
119.0
|
133.0
|
Cash Flow per Share
2 |
3.000
|
2.850
|
1.510
|
5.160
|
0.7200
|
6.420
|
Capex
1 |
115
|
150
|
227
|
1,138
|
793
|
1,238
|
Capex / Sales
|
3.52%
|
4.05%
|
5.52%
|
17.32%
|
11.66%
|
18.39%
|
Announcement Date
|
21/08/18
|
07/09/19
|
06/10/20
|
08/09/21
|
07/09/22
|
07/09/23
|
|
1st Jan change
|
Capi.
|
---|
| -10.58% | 111M | | +55.32% | 815B | | +44.05% | 641B | | -6.75% | 352B | | +13.56% | 314B | | +10.68% | 303B | | +16.57% | 242B | | +13.31% | 218B | | +8.48% | 168B | | -2.81% | 159B |
Other Pharmaceuticals
|